A walking, human-shaped robot now costs less than a used car, and the company that got it there is not in Silicon Valley but in Hangzhou. The bet buried in Unitree's price tags: the humanoid contest may not be an AI race at all but a manufacturing race, won by whoever can build cheap bodies by the million and let the brain catch up. Inside the one joint that sets the price, the reflexes learned from a million simulated falls, the supply chain that makes it all cheap, and the three ways body-first could still lose.

A psychedelic is about to become prescription medicine for the first time since 1970, and the molecule winning the race is the one that kept the trip, even as the smart money bets that trip is a deletable side effect. The deeper claim: these may not be 'mind-manifesting' experiences but psychoplastogens, molecules that physically regrow the brain's withered wiring.

Yamanaka's 2006 discovery showed cell identity is reversible. Today's bet is that you can wind a cell halfway back, recovering youth without erasing identity. The biology of partial reprogramming, the four-billion-dollar race to commercialize it, and what a real win looks like.